Repositioning Candidate Details
| Candidate ID: | R0016 |
| Source ID: | DB00049 |
| Source Type: | approved; investigational |
| Compound Type: | biotech |
| Compound Name: | Rasburicase |
| Synonyms: | Rasburicase; Urate oxidase |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_. |
| CAS Number: | 134774-45-1 |
| Molecular Weight: | |
| DrugBank Indication: | For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy) |
| DrugBank Pharmacology: | Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis. |
| DrugBank MoA: | Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin). |
| Targets: | Uric acid metabolizer |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |